01.06.2022 – Helmut Jeggle was reappointed as Chairman of the Supervisory Board
In addition, Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl will complement the Supervisory Board as additional members, reflecting BioNTech’s growth with additional expertise in finance, governance and international markets. All three members will serve in their roles until the AGM 2026.
In addition, the shareholders passed the proposal of the Management Board and Supervisory Board to pay a special cash dividend of €2.00 per ordinary share (incl. those held in the form of ADSs) in addition to the repurchase program of BioNTech shares in the amount of up to $1.5 billion over the next two years.
“Over the past two years, BioNTech has developed into a fully integrated biotech company with a diversified clinical pipeline, including several late-staged product candidates. We want our shareholders to participate in our strong 2021 performance via a special cash dividend and a share repurchase program. This is in line with BioNTech’s capital allocation strategy and the company’s commitment to delivering shareholder value,” said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech. “With Prof. Dr. Anja Morawietz and Prof. Dr. Rudolf Staudigl, we are gaining further expertise in finance, governance and international markets, which will complement the existing skillset of the Board. I am grateful for the
opportunity to continue to serve this company as Chairman of the Supervisory Board.”
Read more: Download Press release